Naronapride is a late-stage oral gastro-prokinetic drug that has shown efficacy in treating a wide range of gastrointestinal disorders, including chronic idiopathic constipation, functional dyspepsia, gastroparesis, gastroesophageal reflux disease, short bowel syndrome, enteral feeding intolerance, and post-operative ileus. With at least 16% of people worldwide suffering from GI-related disorders and currently approved therapies falling short, naronapride has the potential to address major GI indications associated with dysmotility, as well as unmet therapeutic needs in both chronic and acute GI-related indications.